임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 23:04
논문번호 77
논문제목(영문) Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation.
국내외구분 국내 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Park KH
교신저자명 Jeong MH
공동저자명 Park KH, Jeong MH, Lee MG, Ko JS, Lee SE, Kang WY, Kim SH, Sim DS, Yoon NS, Youn HJ, Hong YJ, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC;
게제년월일 2009-01-01
ISSN 1738-5520
Impact Factor 0.753
학술지명 Korean Circ J.
서지사항 0집 / 39권 / 5호,   페이지(190 - 197)
요약초록문
(Abstract) 입력		 BACKGROUND AND OBJECTIVES:
Triple anti-platelet therapy is known to prevent restenosis after drug-eluting stent (DES) implantation. However, there is little available data concerning the efficacy of triple anti-platelet therapy for acute myocardial infarction (AMI).
SUBJECTS AND METHODS:
We analyzed 528 consecutive patients with AMI undergoing DES implantation between Nov 2005 and Apr 2008. We compared clinical outcomes in the triple anti-platelet therapy (group I, n=413: cilostazol combined with aspirin and clopidogrel for at least one month) and dual antiplatelet therapy groups (group II, n=115: aspirin and clopidogrel).
RESULTS:
There were no significant differences in baseline characteristics. However, ST elevation myocardial infarction (STEMI) and use of TAXUS(R) stents were more common (70.9% vs. 55.7%, p=0.002; 83.5% vs. 73.0%, p=0.011) in Group I. Group I had lower incidences of cardiac death, 6-month target lesion revascularization (TLR), and major adverse cardiac and cerebrovascular events (MACCE) compared to Group II (1.7% vs. 5.7%, p=0.022; 5.7% vs. 11.5%, 0.035; 7.9% vs. 16.0%, p=0.011). On subgroup analysis, the incidence of 6-month TLR was lower among patients with American College of Cardiology/American Heart Association (ACC/AHA) B2 or C lesions and non-STEMI (6.0% vs. 14.9%, p=0.012; 4.3% vs. 19.1%, p=0.002) in Group I compared to those in Group II. The rates of bleeding complications were no different between the two groups. On multivariate analysis, Killip III or IV and triple anti-platelet therapy were independent predictors of 6-month MACCE {hazard ratio (HR)=3.382; 95% confidence interval (CI)=1.384-8.262, HR=0.436; 95% CI=0.203-0.933}.
CONCLUSION:
Triple anti-platelet therapy is safe and efficacious, and it prevents TLR in patients with AMI, especially those with complex lesions and non-STEMIs.
파일  C77.+Korean+Circ+J.+2009;39(5)190-197..pdf (437.8K) DATE : 2021-05-25 11:14:43